| Reduction in mobility and COVID-19 transmission P Nouvellet, S Bhatia, A Cori, KEC Ainslie, M Baguelin, S Bhatt, ... Nature communications 12 (1), 1-9, 2021 | 637 | 2021 |
| Recommendations for enterovirus diagnostics and characterisation within and beyond Europe H Harvala, E Broberg, K Benschop, N Berginc, S Ladhani, P Susi, ... Journal of clinical virology 101, 11-17, 2018 | 250 | 2018 |
| Comparison of molecular testing strategies for COVID-19 control: a mathematical modelling study NC Grassly, M Pons-Salort, EPK Parker, PJ White, NM Ferguson, ... The Lancet Infectious Diseases 20 (12), 1381-1389, 2020 | 219 | 2020 |
| Response to COVID-19 in South Korea and implications for lifting stringent interventions A Dighe, L Cattarino, G Cuomo-Dannenburg, J Skarp, N Imai, S Bhatia, ... BMC medicine 18, 1-12, 2020 | 210 | 2020 |
| The epidemiology of non-polio enteroviruses: recent advances and outstanding questions M Pons-Salort, EPK Parker, NC Grassly Current opinion in infectious diseases 28 (5), 479-487, 2015 | 184 | 2015 |
| Serotype-specific immunity explains the incidence of diseases caused by human enteroviruses M Pons-Salort, NC Grassly Science 361 (6404), 800-803, 2018 | 124 | 2018 |
| The seasonality of nonpolio enteroviruses in the United States: patterns and drivers M Pons-Salort, MS Oberste, MA Pallansch, GR Abedi, S Takahashi, ... Proceedings of the National Academy of Sciences 115 (12), 3078-3083, 2018 | 118 | 2018 |
| Comparing human papillomavirus prevalences in women with normal cytology or invasive cervical cancer to rank genotypes according to their oncogenic potential: a meta-analysis … E Bernard, M Pons-Salort, M Favre, I Heard, E Delarocque-Astagneau, ... BMC infectious diseases 13, 1-11, 2013 | 85 | 2013 |
| Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame EPK Parker, NA Molodecky, M Pons-Salort, KM O’Reilly, NC Grassly Expert review of vaccines 14 (8), 1113-1123, 2015 | 79 | 2015 |
| Type 2 poliovirus detection after global withdrawal of trivalent oral vaccine IM Blake, M Pons-Salort, NA Molodecky, OM Diop, P Chenoweth, ... New England Journal of Medicine 379 (9), 834-845, 2018 | 65 | 2018 |
| Epidemiological dynamics of enterovirus D68 in the United States and implications for acute flaccid myelitis SW Park, M Pons-Salort, K Messacar, C Cook, L Meyers, J Farrar, ... Science Translational Medicine 13 (584), eabd2400, 2021 | 58 | 2021 |
| Preventing vaccine-derived poliovirus emergence during the polio endgame M Pons-Salort, CC Burns, H Lyons, IM Blake, H Jafari, MS Oberste, ... PLoS pathogens 12 (7), e1005728, 2016 | 52 | 2016 |
| Exploring individual HPV coinfections is essential to predict HPV-vaccination impact on genotype distribution: a model-based approach M Pons-Salort, V Letort, M Favre, I Heard, B Dervaux, L Opatowski, ... Vaccine 31 (8), 1238-1245, 2013 | 31 | 2013 |
| The role of genetic sequencing and analysis in the polio eradication programme D Jorgensen, M Pons-Salort, AG Shaw, NC Grassly Virus Evolution 6 (2), veaa040, 2020 | 26 | 2020 |
| Insights into persistence mechanisms of a zoonotic virus in bat colonies using a multispecies metapopulation model M Pons-Salort, J Serra-Cobo, F Jay, M Lopez-Roig, R Lavenir, ... PLoS one 9 (4), e95610, 2014 | 23 | 2014 |
| Population immunity against serotype-2 poliomyelitis leading up to the global withdrawal of the oral poliovirus vaccine: spatio-temporal modelling of surveillance data M Pons-Salort, NA Molodecky, KM O’Reilly, MZ Wadood, RM Safdar, ... PLoS medicine 13 (10), e1002140, 2016 | 19 | 2016 |
| Interaction of vaccination and reduction of antibiotic use drives unexpected increase of pneumococcal meningitis M Domenech de Cellès, M Pons-Salort, E Varon, MA Vibet, C Ligier, ... Scientific Reports 5 (1), 11293, 2015 | 17 | 2015 |
| Report 31: Estimating the burden of COVID-19 in Damascus, Syria: an analysis of novel data sources to infer mortality under-ascertainment O Watson, M Alhaffar, Z Mehchy Imperial College London, doi 10 (82443), 15, 2020 | 16 | 2020 |
| HPV genotype replacement: too early to tell M Pons-Salort, ACM Thiébaut, D Guillemot, M Favre, ... The Lancet Infectious Diseases 13 (12), 1012, 2013 | 16 | 2013 |
| A computational framework to assess the efficacy of cytotoxic molecules and vascular disrupting agents against solid tumours M Pons-Salort, B van der Sanden, A Juhem, A Popov, A Stéphanou Mathematical Modelling of Natural Phenomena 7 (1), 49-77, 2012 | 13 | 2012 |
